Candel Therapeutics, Inc. CADL Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s other commercial liabilities?
- Candel Therapeutics, Inc. (CADL) reported other commercial liabilities of $3.47M in Q1 2026.
- How has Candel Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Candel Therapeutics, Inc.'s other commercial liabilities increased by 27.7% year-over-year, from $2.72M to $3.47M.
- What is the long-term trend for Candel Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s other commercial liabilities has grown at a 18.5% compound annual growth rate (CAGR), from $3.14M to $7.33M.